Related references
Note: Only part of the references are listed.BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition
Zhan Yao et al.
CANCER CELL (2015)
First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014
Bristi Basu et al.
CLINICAL CANCER RESEARCH (2015)
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Dejan Juric et al.
NATURE (2015)
Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer
Nikhil Wagle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
Brian C. Grabiner et al.
CANCER DISCOVERY (2014)
Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
Nikhil Wagle et al.
CANCER DISCOVERY (2014)
mTOR kinase structure, mechanism and regulation
Haijuan Yang et al.
NATURE (2013)
The Best of Both Worlds? Bitopic Orthosteric/Allosteric Ligands of G Protein-Coupled Receptors
Celine Valant et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 52 (2012)
The translational landscape of mTOR signalling steers cancer initiation and metastasis
Andrew C. Hsieh et al.
NATURE (2012)
Genome Sequencing Identifies a Basis for Everolimus Sensitivity
Gopa Iyer et al.
SCIENCE (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK
Damian F. Brennan et al.
NATURE (2011)
mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
Vanessa S. Rodrik-Outmezguine et al.
CANCER DISCOVERY (2011)
Design and synthesis of benzoazepin-2-one analogs as allosteric binders targeting the PIF pocket of PDK1
Linyi Wei et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Analysis of Kinase Inhibitor Selectivity using a Thermodynamics-Based Partition Index
Alan C. Cheng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs
Ryan J. O. Dowling et al.
SCIENCE (2010)
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
Carson C. Thoreen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
FK506-binding protein (FKBP) partitions a modified HIV protease inhibitor into blood cells and prolongs its lifetime in vivo
Paul S. Marinec et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Morris E. Feldman et al.
PLOS BIOLOGY (2009)
Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy
BG Szczepankiewicz et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2003)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)